 Douglas Seals
Concepts (774)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 200 | 2026 | 1919 | 20.590 |
Why?
| | Endothelium, Vascular | 87 | 2025 | 941 | 15.290 |
Why?
| | Vascular Stiffness | 46 | 2025 | 450 | 9.850 |
Why?
| | Oxidative Stress | 68 | 2026 | 1322 | 8.450 |
Why?
| | Exercise | 103 | 2025 | 2112 | 8.100 |
Why?
| | Vasodilation | 63 | 2025 | 512 | 8.020 |
Why?
| | Arteries | 33 | 2024 | 260 | 6.480 |
Why?
| | Brachial Artery | 40 | 2025 | 205 | 6.270 |
Why?
| | Sympathetic Nervous System | 68 | 2025 | 173 | 6.180 |
Why?
| | Blood Pressure | 105 | 2025 | 1740 | 6.080 |
Why?
| | Biomedical Research | 12 | 2024 | 681 | 4.900 |
Why?
| | Writing | 8 | 2024 | 99 | 4.580 |
Why?
| | Carotid Arteries | 29 | 2025 | 202 | 4.280 |
Why?
| | Aorta | 20 | 2025 | 423 | 4.070 |
Why?
| | Vascular Diseases | 15 | 2023 | 244 | 3.650 |
Why?
| | Antioxidants | 25 | 2026 | 593 | 3.490 |
Why?
| | Nitric Oxide | 34 | 2025 | 894 | 3.340 |
Why?
| | Regional Blood Flow | 36 | 2020 | 497 | 3.210 |
Why?
| | Cardiovascular Diseases | 29 | 2025 | 2091 | 3.150 |
Why?
| | Physiology | 5 | 2024 | 13 | 3.040 |
Why?
| | Physical Endurance | 48 | 2016 | 276 | 3.010 |
Why?
| | Publishing | 5 | 2023 | 109 | 3.000 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 2.950 |
Why?
| | Heart Rate | 84 | 2023 | 834 | 2.920 |
Why?
| | Endothelial Cells | 22 | 2025 | 814 | 2.730 |
Why?
| | Postmenopause | 27 | 2025 | 369 | 2.730 |
Why?
| | Resistance Training | 5 | 2023 | 169 | 2.660 |
Why?
| | Aged | 181 | 2026 | 24771 | 2.610 |
Why?
| | Hypertension | 24 | 2025 | 1250 | 2.560 |
Why?
| | Dietary Supplements | 21 | 2026 | 567 | 2.440 |
Why?
| | Mitochondria | 11 | 2026 | 962 | 2.400 |
Why?
| | Blood Vessels | 6 | 2020 | 173 | 2.330 |
Why?
| | Caloric Restriction | 10 | 2021 | 125 | 2.330 |
Why?
| | Pulse Wave Analysis | 24 | 2025 | 239 | 2.290 |
Why?
| | Middle Aged | 202 | 2026 | 34553 | 2.270 |
Why?
| | Physical Exertion | 34 | 2014 | 208 | 2.210 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 38 | 2.160 |
Why?
| | Male | 265 | 2026 | 69945 | 2.060 |
Why?
| | Humans | 354 | 2026 | 141010 | 2.040 |
Why?
| | Inflammation | 24 | 2024 | 2835 | 2.030 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 199 | 2.020 |
Why?
| | Exercise Tolerance | 9 | 2025 | 281 | 2.010 |
Why?
| | Muscles | 32 | 2023 | 331 | 1.970 |
Why?
| | Ascorbic Acid | 17 | 2025 | 180 | 1.970 |
Why?
| | Physical Fitness | 20 | 2013 | 206 | 1.970 |
Why?
| | Cellular Senescence | 10 | 2025 | 205 | 1.960 |
Why?
| | Baroreflex | 16 | 2016 | 57 | 1.930 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 246 | 1.900 |
Why?
| | Methylamines | 6 | 2022 | 40 | 1.870 |
Why?
| | Oxygen Consumption | 47 | 2023 | 712 | 1.870 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 44 | 1.860 |
Why?
| | NF-kappa B | 9 | 2015 | 684 | 1.840 |
Why?
| | Peer Review | 4 | 2023 | 45 | 1.810 |
Why?
| | Superoxides | 16 | 2022 | 208 | 1.800 |
Why?
| | Vasodilator Agents | 12 | 2024 | 330 | 1.770 |
Why?
| | Acetylcholine | 12 | 2023 | 204 | 1.670 |
Why?
| | Mice | 57 | 2026 | 17945 | 1.580 |
Why?
| | Norepinephrine | 29 | 2011 | 189 | 1.570 |
Why?
| | Animals | 88 | 2026 | 37304 | 1.570 |
Why?
| | Adult | 203 | 2025 | 39198 | 1.520 |
Why?
| | Diet, Western | 3 | 2022 | 81 | 1.510 |
Why?
| | Heart | 16 | 2018 | 616 | 1.490 |
Why?
| | Female | 182 | 2025 | 75619 | 1.470 |
Why?
| | Adipose Tissue | 19 | 2018 | 645 | 1.430 |
Why?
| | Healthy Aging | 4 | 2024 | 37 | 1.420 |
Why?
| | Vascular Resistance | 20 | 2012 | 364 | 1.390 |
Why?
| | Mice, Inbred C57BL | 30 | 2026 | 5849 | 1.380 |
Why?
| | Motor Activity | 8 | 2024 | 717 | 1.340 |
Why?
| | Respiratory Muscles | 5 | 2023 | 35 | 1.310 |
Why?
| | Salicylates | 5 | 2015 | 29 | 1.310 |
Why?
| | Forearm | 18 | 2023 | 139 | 1.300 |
Why?
| | NADPH Oxidases | 13 | 2020 | 131 | 1.270 |
Why?
| | Reactive Oxygen Species | 15 | 2026 | 630 | 1.220 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 78 | 1.210 |
Why?
| | Research Personnel | 4 | 2023 | 177 | 1.210 |
Why?
| | Muscle, Skeletal | 24 | 2026 | 1747 | 1.200 |
Why?
| | Age Factors | 29 | 2025 | 3291 | 1.180 |
Why?
| | Double-Blind Method | 17 | 2025 | 1979 | 1.160 |
Why?
| | Estrogens | 8 | 2023 | 367 | 1.150 |
Why?
| | Tyrosine | 14 | 2020 | 229 | 1.120 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 35 | 1.110 |
Why?
| | Vasoconstriction | 7 | 2017 | 215 | 1.100 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 282 | 1.060 |
Why?
| | Femoral Artery | 11 | 2013 | 184 | 1.050 |
Why?
| | NAD | 5 | 2023 | 78 | 1.030 |
Why?
| | Doxorubicin | 4 | 2025 | 369 | 1.020 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 1.010 |
Why?
| | Geriatrics | 4 | 2015 | 96 | 1.010 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 1.010 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 142 | 1.000 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 346 | 0.990 |
Why?
| | Inflammation Mediators | 6 | 2025 | 507 | 0.980 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 66 | 0.960 |
Why?
| | Metabolomics | 4 | 2021 | 702 | 0.910 |
Why?
| | Longevity | 4 | 2015 | 174 | 0.910 |
Why?
| | Cross-Over Studies | 11 | 2026 | 577 | 0.910 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 33 | 0.890 |
Why?
| | Interleukin-1 | 5 | 2022 | 970 | 0.880 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 3 | 0.880 |
Why?
| | Curcumin | 2 | 2017 | 28 | 0.880 |
Why?
| | Elasticity | 11 | 2017 | 193 | 0.880 |
Why?
| | Drinking Water | 2 | 2022 | 94 | 0.850 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.850 |
Why?
| | Habits | 7 | 2017 | 51 | 0.850 |
Why?
| | Niacinamide | 4 | 2025 | 82 | 0.840 |
Why?
| | Trehalose | 4 | 2017 | 33 | 0.820 |
Why?
| | Career Choice | 2 | 2024 | 233 | 0.820 |
Why?
| | Cardiorespiratory Fitness | 3 | 2025 | 69 | 0.810 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 716 | 0.810 |
Why?
| | Body Composition | 30 | 2012 | 703 | 0.810 |
Why?
| | Financing, Organized | 1 | 2023 | 35 | 0.810 |
Why?
| | Physical Education and Training | 15 | 2024 | 73 | 0.800 |
Why?
| | Peer Review, Research | 1 | 2023 | 31 | 0.800 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 102 | 0.800 |
Why?
| | Compliance | 15 | 2017 | 50 | 0.800 |
Why?
| | Research Support as Topic | 1 | 2023 | 81 | 0.800 |
Why?
| | Fenofibrate | 2 | 2013 | 27 | 0.780 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 108 | 0.780 |
Why?
| | Elastin | 6 | 2023 | 79 | 0.770 |
Why?
| | Goals | 1 | 2024 | 177 | 0.770 |
Why?
| | Vaping | 1 | 2023 | 63 | 0.770 |
Why?
| | Glycation End Products, Advanced | 4 | 2025 | 85 | 0.760 |
Why?
| | Young Adult | 29 | 2025 | 13675 | 0.750 |
Why?
| | Lyases | 1 | 2022 | 15 | 0.750 |
Why?
| | Sodium, Dietary | 4 | 2013 | 38 | 0.750 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.750 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 93 | 0.750 |
Why?
| | Transcriptome | 3 | 2023 | 1007 | 0.740 |
Why?
| | Muscle Strength | 6 | 2023 | 328 | 0.740 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 105 | 0.730 |
Why?
| | Research Design | 4 | 2022 | 1105 | 0.730 |
Why?
| | Rest | 13 | 2007 | 128 | 0.730 |
Why?
| | Obesity | 14 | 2023 | 2999 | 0.720 |
Why?
| | Speech | 1 | 2022 | 74 | 0.720 |
Why?
| | Hemodynamics | 17 | 2023 | 1105 | 0.720 |
Why?
| | Stress, Physiological | 12 | 2017 | 449 | 0.720 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.710 |
Why?
| | Vagus Nerve | 7 | 2005 | 88 | 0.710 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.710 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.700 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.700 |
Why?
| | Leg | 14 | 2007 | 238 | 0.700 |
Why?
| | Spin Labels | 8 | 2020 | 53 | 0.700 |
Why?
| | Models, Animal | 6 | 2024 | 391 | 0.690 |
Why?
| | Running | 16 | 2017 | 229 | 0.680 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1220 | 0.680 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 346 | 0.670 |
Why?
| | Reference Values | 26 | 2021 | 803 | 0.670 |
Why?
| | Autophagy | 3 | 2017 | 283 | 0.670 |
Why?
| | Ubiquinone | 2 | 2026 | 35 | 0.660 |
Why?
| | Isometric Contraction | 14 | 1996 | 184 | 0.660 |
Why?
| | Comprehension | 1 | 2022 | 182 | 0.650 |
Why?
| | Biomarkers | 19 | 2025 | 4178 | 0.650 |
Why?
| | Life Style | 14 | 2017 | 479 | 0.650 |
Why?
| | Frailty | 2 | 2024 | 177 | 0.650 |
Why?
| | Cardiac Output | 15 | 2004 | 177 | 0.650 |
Why?
| | Cytokines | 10 | 2019 | 2077 | 0.650 |
Why?
| | Fasting | 2 | 2020 | 283 | 0.640 |
Why?
| | Exercise Therapy | 9 | 2025 | 451 | 0.640 |
Why?
| | Nitroglycerin | 3 | 2020 | 14 | 0.630 |
Why?
| | Organophosphorus Compounds | 2 | 2026 | 82 | 0.620 |
Why?
| | Dementia | 1 | 2023 | 269 | 0.620 |
Why?
| | Spermidine | 2 | 2024 | 18 | 0.610 |
Why?
| | Nitrites | 3 | 2014 | 88 | 0.610 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2025 | 623 | 0.600 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 40 | 0.600 |
Why?
| | Cardiovascular System | 10 | 2020 | 137 | 0.590 |
Why?
| | Overweight | 3 | 2009 | 587 | 0.590 |
Why?
| | Isoproterenol | 4 | 2007 | 101 | 0.590 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 97 | 0.580 |
Why?
| | Mentoring | 1 | 2021 | 149 | 0.580 |
Why?
| | Sirtuin 1 | 3 | 2016 | 33 | 0.580 |
Why?
| | Energy Metabolism | 9 | 2007 | 926 | 0.580 |
Why?
| | Adolescent | 46 | 2023 | 22066 | 0.580 |
Why?
| | Lipids | 6 | 2018 | 686 | 0.580 |
Why?
| | Sex Characteristics | 13 | 2011 | 781 | 0.570 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 561 | 0.560 |
Why?
| | Amino Acids | 2 | 2019 | 491 | 0.560 |
Why?
| | Health Status | 3 | 2019 | 822 | 0.550 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 112 | 0.550 |
Why?
| | Body Constitution | 4 | 2005 | 54 | 0.550 |
Why?
| | Blood Volume | 8 | 1998 | 65 | 0.550 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 31 | 0.540 |
Why?
| | Tunica Intima | 7 | 2006 | 76 | 0.530 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 445 | 0.530 |
Why?
| | Diet | 6 | 2024 | 1271 | 0.520 |
Why?
| | Nitroprusside | 5 | 2011 | 72 | 0.520 |
Why?
| | Epinephrine | 14 | 2007 | 147 | 0.510 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2122 | 0.510 |
Why?
| | Serine | 2 | 2015 | 148 | 0.500 |
Why?
| | Extracellular Matrix | 1 | 2021 | 554 | 0.500 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 85 | 0.500 |
Why?
| | Glucose | 4 | 2019 | 1027 | 0.500 |
Why?
| | Basal Metabolism | 4 | 2004 | 63 | 0.500 |
Why?
| | Diet Therapy | 1 | 2016 | 37 | 0.500 |
Why?
| | Muscle Contraction | 13 | 2003 | 430 | 0.500 |
Why?
| | Cognition | 3 | 2025 | 1226 | 0.480 |
Why?
| | Primary Prevention | 1 | 2018 | 202 | 0.480 |
Why?
| | Time Factors | 21 | 2021 | 6939 | 0.480 |
Why?
| | Estradiol | 3 | 2021 | 523 | 0.470 |
Why?
| | Premenopause | 9 | 2025 | 120 | 0.470 |
Why?
| | Aniline Compounds | 3 | 2025 | 120 | 0.470 |
Why?
| | Blood Glucose | 10 | 2017 | 2274 | 0.440 |
Why?
| | Cross-Sectional Studies | 22 | 2020 | 5648 | 0.440 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 19 | 0.440 |
Why?
| | Hand Strength | 4 | 2025 | 132 | 0.440 |
Why?
| | Collagen | 3 | 2021 | 452 | 0.440 |
Why?
| | Reflex | 6 | 2001 | 71 | 0.440 |
Why?
| | Body Mass Index | 18 | 2015 | 2377 | 0.440 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2025 | 133 | 0.440 |
Why?
| | Flavonols | 2 | 2025 | 19 | 0.440 |
Why?
| | Risk Factors | 19 | 2021 | 10475 | 0.430 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 195 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.430 |
Why?
| | Geriatric Assessment | 2 | 2015 | 225 | 0.420 |
Why?
| | Niacin | 1 | 2013 | 16 | 0.420 |
Why?
| | Nitrates | 4 | 2022 | 96 | 0.420 |
Why?
| | Proteome | 1 | 2018 | 483 | 0.420 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.410 |
Why?
| | Atherosclerosis | 1 | 2018 | 402 | 0.410 |
Why?
| | Vitamin B Complex | 1 | 2013 | 40 | 0.410 |
Why?
| | Hindlimb | 1 | 2014 | 133 | 0.410 |
Why?
| | Locomotion | 1 | 2014 | 106 | 0.400 |
Why?
| | Eating | 2 | 2007 | 393 | 0.390 |
Why?
| | Aortic Diseases | 1 | 2014 | 119 | 0.390 |
Why?
| | Exercise Test | 12 | 2021 | 620 | 0.390 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 227 | 0.380 |
Why?
| | Arm | 7 | 2008 | 109 | 0.380 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.380 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 9 | 0.380 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 114 | 0.380 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 62 | 0.370 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 44 | 0.370 |
Why?
| | Allopurinol | 2 | 2016 | 68 | 0.370 |
Why?
| | Pressoreceptors | 6 | 2001 | 19 | 0.360 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 2047 | 0.360 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 76 | 0.350 |
Why?
| | Arteritis | 1 | 2011 | 25 | 0.350 |
Why?
| | Adrenal Glands | 3 | 2000 | 79 | 0.340 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 141 | 0.340 |
Why?
| | C-Reactive Protein | 3 | 2022 | 416 | 0.340 |
Why?
| | Postural Balance | 1 | 2014 | 237 | 0.340 |
Why?
| | Oxidants | 1 | 2011 | 104 | 0.340 |
Why?
| | Ultrasonography | 11 | 2017 | 765 | 0.340 |
Why?
| | Systole | 6 | 2020 | 175 | 0.330 |
Why?
| | Uric Acid | 1 | 2012 | 163 | 0.330 |
Why?
| | Behavior, Animal | 1 | 2014 | 513 | 0.330 |
Why?
| | Colorado | 6 | 2024 | 4595 | 0.330 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 360 | 0.330 |
Why?
| | Athletic Performance | 2 | 2012 | 81 | 0.330 |
Why?
| | Pilot Projects | 5 | 2025 | 1817 | 0.320 |
Why?
| | Analysis of Variance | 7 | 2011 | 1312 | 0.320 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 200 | 0.320 |
Why?
| | Athletes | 2 | 2022 | 413 | 0.310 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2162 | 0.310 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 169 | 0.310 |
Why?
| | Metabolome | 3 | 2018 | 366 | 0.300 |
Why?
| | Peroxidase | 1 | 2010 | 174 | 0.300 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 33 | 0.300 |
Why?
| | Interleukins | 2 | 2022 | 250 | 0.300 |
Why?
| | Extremities | 2 | 2001 | 140 | 0.300 |
Why?
| | Blood Circulation | 4 | 2021 | 44 | 0.300 |
Why?
| | Hot Temperature | 5 | 1993 | 405 | 0.300 |
Why?
| | Biological Availability | 4 | 2021 | 137 | 0.300 |
Why?
| | Vitamin D | 2 | 2017 | 393 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 188 | 0.290 |
Why?
| | Interleukin-6 | 4 | 2024 | 775 | 0.290 |
Why?
| | Healthy Volunteers | 3 | 2018 | 212 | 0.290 |
Why?
| | Administration, Oral | 5 | 2015 | 824 | 0.290 |
Why?
| | Cells, Cultured | 5 | 2025 | 4149 | 0.290 |
Why?
| | Endothelin-1 | 2 | 2009 | 177 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1864 | 0.280 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 49 | 0.280 |
Why?
| | Energy Intake | 6 | 2020 | 510 | 0.280 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 47 | 0.280 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 513 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 571 | 0.280 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 271 | 0.280 |
Why?
| | Collagen Type I | 3 | 2014 | 140 | 0.280 |
Why?
| | Kidney | 7 | 2025 | 1480 | 0.280 |
Why?
| | Signal Transduction | 6 | 2014 | 5114 | 0.280 |
Why?
| | Peroneal Nerve | 5 | 2000 | 18 | 0.280 |
Why?
| | Upper Extremity | 1 | 2009 | 110 | 0.280 |
Why?
| | Oxygen | 11 | 2022 | 985 | 0.280 |
Why?
| | Posture | 6 | 2001 | 193 | 0.280 |
Why?
| | Cognitive Dysfunction | 2 | 2025 | 416 | 0.270 |
Why?
| | Sports | 5 | 2003 | 219 | 0.270 |
Why?
| | Hypercapnia | 2 | 2025 | 54 | 0.270 |
Why?
| | Phosphorylation | 6 | 2013 | 1753 | 0.270 |
Why?
| | Abdomen | 5 | 2004 | 138 | 0.270 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 418 | 0.270 |
Why?
| | Adiposity | 1 | 2012 | 519 | 0.270 |
Why?
| | Treatment Outcome | 7 | 2025 | 11195 | 0.260 |
Why?
| | Regression Analysis | 10 | 2011 | 1013 | 0.260 |
Why?
| | Human Experimentation | 1 | 2007 | 13 | 0.260 |
Why?
| | Acetophenones | 3 | 2019 | 13 | 0.260 |
Why?
| | Trimethaphan | 5 | 2005 | 6 | 0.260 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 833 | 0.260 |
Why?
| | Swimming | 5 | 2002 | 49 | 0.250 |
Why?
| | Tunica Media | 3 | 2001 | 36 | 0.250 |
Why?
| | Phenylephrine | 5 | 2005 | 75 | 0.250 |
Why?
| | Electrocardiography | 9 | 2005 | 626 | 0.250 |
Why?
| | Congresses as Topic | 2 | 2018 | 223 | 0.250 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 241 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2600 | 0.250 |
Why?
| | Proteins | 3 | 2009 | 1007 | 0.250 |
Why?
| | Hypoxia | 6 | 1999 | 1163 | 0.250 |
Why?
| | Pyridinium Compounds | 3 | 2025 | 29 | 0.250 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 547 | 0.240 |
Why?
| | Sulfonamides | 3 | 2025 | 568 | 0.240 |
Why?
| | Fatty Acids | 2 | 2019 | 446 | 0.240 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 269 | 0.240 |
Why?
| | Microcirculation | 2 | 2019 | 137 | 0.240 |
Why?
| | Thermogenesis | 1 | 2005 | 46 | 0.230 |
Why?
| | Recovery of Function | 4 | 2017 | 683 | 0.230 |
Why?
| | Brain | 6 | 2023 | 2857 | 0.230 |
Why?
| | Carbon Dioxide | 3 | 2023 | 241 | 0.230 |
Why?
| | Aged, 80 and over | 14 | 2025 | 7939 | 0.230 |
Why?
| | Pyruvaldehyde | 1 | 2025 | 50 | 0.230 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 45 | 0.230 |
Why?
| | Cell Nucleus | 1 | 2008 | 607 | 0.230 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 20 | 0.230 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 41 | 0.230 |
Why?
| | Arginine | 1 | 2006 | 256 | 0.230 |
Why?
| | MicroRNAs | 1 | 2011 | 693 | 0.220 |
Why?
| | Flavonoids | 1 | 2025 | 81 | 0.220 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 44 | 0.220 |
Why?
| | American Heart Association | 2 | 2020 | 299 | 0.220 |
Why?
| | Mitochondria, Muscle | 1 | 2026 | 120 | 0.220 |
Why?
| | Preventive Medicine | 2 | 2015 | 40 | 0.220 |
Why?
| | Acidosis | 1 | 2025 | 103 | 0.220 |
Why?
| | Veins | 5 | 2009 | 69 | 0.210 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.210 |
Why?
| | Case-Control Studies | 4 | 2025 | 3575 | 0.210 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.210 |
Why?
| | Skin | 4 | 2019 | 760 | 0.200 |
Why?
| | Weight Loss | 2 | 2008 | 789 | 0.200 |
Why?
| | Lactates | 7 | 2007 | 85 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 217 | 0.200 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 81 | 0.200 |
Why?
| | Blueberry Plants | 1 | 2023 | 7 | 0.200 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 82 | 0.200 |
Why?
| | Hand | 8 | 1994 | 163 | 0.190 |
Why?
| | History, 20th Century | 1 | 2024 | 323 | 0.190 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 411 | 0.190 |
Why?
| | Myocardium | 5 | 2010 | 911 | 0.190 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 191 | 0.190 |
Why?
| | Apoptosis | 1 | 2011 | 2479 | 0.190 |
Why?
| | Cholesterol | 5 | 1997 | 404 | 0.190 |
Why?
| | Anthropometry | 3 | 2011 | 208 | 0.190 |
Why?
| | Kidney Diseases | 2 | 2025 | 409 | 0.190 |
Why?
| | Authorship | 1 | 2023 | 44 | 0.190 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.190 |
Why?
| | Supine Position | 6 | 1999 | 38 | 0.190 |
Why?
| | Fibrinolysis | 2 | 2008 | 162 | 0.190 |
Why?
| | Sugars | 1 | 2022 | 42 | 0.190 |
Why?
| | Adrenal Medulla | 1 | 2002 | 9 | 0.180 |
Why?
| | Cold Temperature | 7 | 2001 | 196 | 0.180 |
Why?
| | Respiration | 7 | 1998 | 209 | 0.180 |
Why?
| | Coronary Disease | 6 | 1998 | 372 | 0.180 |
Why?
| | Citrulline | 1 | 2022 | 44 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2023 | 244 | 0.180 |
Why?
| | Body Weight | 10 | 2019 | 992 | 0.180 |
Why?
| | Universities | 1 | 2024 | 450 | 0.180 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 172 | 0.170 |
Why?
| | Sirolimus | 3 | 2021 | 276 | 0.170 |
Why?
| | Fatty Liver | 1 | 2023 | 233 | 0.170 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 54 | 0.170 |
Why?
| | Progesterone | 1 | 2002 | 258 | 0.170 |
Why?
| | Insulin | 11 | 2022 | 2458 | 0.170 |
Why?
| | Weight Gain | 1 | 2004 | 536 | 0.170 |
Why?
| | Nicotine | 1 | 2023 | 339 | 0.170 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 86 | 0.170 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.170 |
Why?
| | Mexican Americans | 1 | 2001 | 112 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 153 | 0.160 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 120 | 0.160 |
Why?
| | Knee | 1 | 2000 | 69 | 0.160 |
Why?
| | DNA Methylation | 2 | 2024 | 642 | 0.160 |
Why?
| | Lipocalin-2 | 1 | 2020 | 79 | 0.160 |
Why?
| | Lung | 4 | 1999 | 4042 | 0.160 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 140 | 0.160 |
Why?
| | Triglycerides | 4 | 2017 | 510 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 179 | 0.160 |
Why?
| | RNA, Untranslated | 1 | 2021 | 124 | 0.160 |
Why?
| | Functional Food | 1 | 2019 | 3 | 0.150 |
Why?
| | Emotions | 1 | 2025 | 576 | 0.150 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 425 | 0.150 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 36 | 0.150 |
Why?
| | Menopause | 2 | 2006 | 317 | 0.150 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 28 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 213 | 0.150 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 42 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 381 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 52 | 0.150 |
Why?
| | Rats | 11 | 2015 | 5556 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 478 | 0.150 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 50 | 0.150 |
Why?
| | Social Class | 1 | 2001 | 269 | 0.150 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 753 | 0.150 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 26 | 0.140 |
Why?
| | Stroke Volume | 7 | 1998 | 598 | 0.140 |
Why?
| | Linear Models | 2 | 2012 | 855 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 269 | 0.140 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 347 | 0.140 |
Why?
| | Cohort Studies | 5 | 2013 | 5795 | 0.140 |
Why?
| | Leptin | 5 | 2019 | 238 | 0.140 |
Why?
| | Methionine | 1 | 2018 | 158 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 281 | 0.140 |
Why?
| | Adipocytes | 1 | 2019 | 220 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 142 | 0.130 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 59 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2021 | 396 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 61 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 65 | 0.130 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 31 | 0.130 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4400 | 0.130 |
Why?
| | Stress, Psychological | 3 | 1995 | 1123 | 0.130 |
Why?
| | Heart Conduction System | 4 | 2002 | 92 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 45 | 0.120 |
Why?
| | Education, Graduate | 1 | 2016 | 33 | 0.120 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 111 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2018 | 1218 | 0.120 |
Why?
| | Students, Health Occupations | 1 | 2016 | 34 | 0.120 |
Why?
| | Age Distribution | 1 | 1997 | 396 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1998 | 268 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 309 | 0.120 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.120 |
Why?
| | Walking | 3 | 2011 | 543 | 0.120 |
Why?
| | Risk Assessment | 2 | 2018 | 3512 | 0.120 |
Why?
| | Program Development | 1 | 2018 | 364 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 298 | 0.120 |
Why?
| | Hemostasis | 2 | 1998 | 100 | 0.120 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 28 | 0.110 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 53 | 0.110 |
Why?
| | Middle Cerebral Artery | 2 | 2025 | 55 | 0.110 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.110 |
Why?
| | Sex Factors | 3 | 2025 | 2048 | 0.110 |
Why?
| | Urinalysis | 1 | 2015 | 77 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 522 | 0.110 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 11 | 0.110 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 11 | 0.110 |
Why?
| | Skinfold Thickness | 4 | 1999 | 46 | 0.110 |
Why?
| | Rotenone | 1 | 2014 | 16 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 19 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 259 | 0.110 |
Why?
| | Neurons | 2 | 1995 | 1611 | 0.100 |
Why?
| | Mobility Limitation | 1 | 2014 | 63 | 0.100 |
Why?
| | Liver | 3 | 2017 | 1812 | 0.100 |
Why?
| | Nutritional Status | 1 | 2016 | 357 | 0.100 |
Why?
| | Plasma Volume | 3 | 2002 | 20 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 95 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 128 | 0.100 |
Why?
| | Cell Cycle | 1 | 2016 | 601 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 919 | 0.100 |
Why?
| | Plethysmography | 4 | 2007 | 108 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1504 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 120 | 0.100 |
Why?
| | Epidemiology | 1 | 2013 | 33 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 250 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 298 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 265 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 72 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 12 | 0.100 |
Why?
| | Body Temperature | 5 | 1991 | 224 | 0.100 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.090 |
Why?
| | Hypotension | 1 | 1993 | 126 | 0.090 |
Why?
| | Catecholamines | 5 | 1996 | 89 | 0.090 |
Why?
| | Mental Processes | 1 | 1992 | 35 | 0.090 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 12 | 0.090 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7797 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 117 | 0.090 |
Why?
| | Waist Circumference | 1 | 2012 | 134 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 6 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 137 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 4 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| | Myography | 1 | 2011 | 8 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 43 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 115 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 78 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 17 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.080 |
Why?
| | Diastole | 3 | 2003 | 141 | 0.080 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 367 | 0.080 |
Why?
| | Connective Tissue | 1 | 2010 | 38 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2022 | 16389 | 0.080 |
Why?
| | Endorphins | 1 | 1990 | 10 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 404 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 57 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.080 |
Why?
| | Caspases | 1 | 2011 | 244 | 0.080 |
Why?
| | United States | 3 | 2020 | 15252 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1080 | 0.080 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.080 |
Why?
| | Benzamides | 1 | 2011 | 218 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 332 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 78 | 0.080 |
Why?
| | Communication | 1 | 2016 | 941 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 135 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 251 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3171 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5212 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 1031 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 83 | 0.080 |
Why?
| | Subclavian Artery | 1 | 1989 | 28 | 0.080 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 26 | 0.080 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 63 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 317 | 0.070 |
Why?
| | Prognosis | 1 | 2018 | 4073 | 0.070 |
Why?
| | Acclimatization | 1 | 1990 | 172 | 0.070 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.070 |
Why?
| | Probability | 1 | 2010 | 307 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 144 | 0.070 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.070 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 19 | 0.070 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 29 | 0.070 |
Why?
| | Homeostasis | 3 | 2021 | 630 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 258 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2511 | 0.070 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 73 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 838 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 80 | 0.070 |
Why?
| | Propranolol | 4 | 2001 | 44 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 249 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 293 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 85 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 145 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 415 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 784 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 48 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 136 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 92 | 0.070 |
Why?
| | Catalase | 1 | 2007 | 134 | 0.060 |
Why?
| | Electrophysiology | 3 | 1993 | 218 | 0.060 |
Why?
| | Databases, Factual | 1 | 2013 | 1445 | 0.060 |
Why?
| | Kinetics | 3 | 1997 | 1620 | 0.060 |
Why?
| | Telomere | 1 | 2010 | 277 | 0.060 |
Why?
| | Amidohydrolases | 1 | 2006 | 32 | 0.060 |
Why?
| | Gene Expression | 1 | 2011 | 1490 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 138 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 374 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2903 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 227 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 142 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 47 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 104 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 747 | 0.060 |
Why?
| | Codon | 1 | 2005 | 92 | 0.060 |
Why?
| | Arterioles | 1 | 2025 | 57 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 44 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 9 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 1010 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 11 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.060 |
Why?
| | Vital Capacity | 2 | 2000 | 305 | 0.050 |
Why?
| | Vasopressins | 1 | 2005 | 60 | 0.050 |
Why?
| | Thigh | 2 | 2003 | 49 | 0.050 |
Why?
| | Calorimetry | 1 | 2004 | 71 | 0.050 |
Why?
| | Loneliness | 1 | 2025 | 54 | 0.050 |
Why?
| | Imidazoles | 1 | 2025 | 250 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1362 | 0.050 |
Why?
| | Osmolar Concentration | 3 | 2001 | 166 | 0.050 |
Why?
| | Up-Regulation | 1 | 2007 | 851 | 0.050 |
Why?
| | Postprandial Period | 1 | 2004 | 111 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2502 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 604 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1196 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2157 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1466 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2815 | 0.050 |
Why?
| | Powders | 1 | 2023 | 41 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 6 | 0.050 |
Why?
| | Hexanols | 1 | 2022 | 7 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 133 | 0.050 |
Why?
| | Biology | 1 | 2023 | 92 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1996 | 0.050 |
Why?
| | Femur | 2 | 2001 | 260 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 8 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 332 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 111 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 5 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 411 | 0.050 |
Why?
| | Phentolamine | 1 | 2001 | 20 | 0.050 |
Why?
| | Mesentery | 1 | 2002 | 45 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.050 |
Why?
| | Ischemia | 5 | 1994 | 413 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2762 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 558 | 0.040 |
Why?
| | Genotype | 1 | 2007 | 1854 | 0.040 |
Why?
| | Men | 1 | 2001 | 22 | 0.040 |
Why?
| | Lactic Acid | 4 | 1995 | 303 | 0.040 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 22 | 0.040 |
Why?
| | Tidal Volume | 2 | 1993 | 103 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2001 | 18 | 0.040 |
Why?
| | Models, Biological | 2 | 2004 | 1810 | 0.040 |
Why?
| | Neurons, Afferent | 2 | 1993 | 101 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1035 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 182 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 229 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 88 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 42 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2524 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 133 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 374 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 95 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 476 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 229 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 72 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 265 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 487 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2069 | 0.040 |
Why?
| | NADP | 1 | 2019 | 51 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 661 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1066 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 25 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 113 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 508 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 845 | 0.030 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 15 | 0.030 |
Why?
| | Prevalence | 2 | 2005 | 2792 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 89 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 409 | 0.030 |
Why?
| | Acute Disease | 1 | 2000 | 1005 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 92 | 0.030 |
Why?
| | Mathematics | 2 | 1996 | 103 | 0.030 |
Why?
| | Automation | 1 | 1997 | 101 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 149 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 647 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 12 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 106 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 27 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1311 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 32 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 114 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 82 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 200 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 215 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 239 | 0.030 |
Why?
| | Pain | 2 | 1992 | 779 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 204 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 196 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1489 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2921 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 12 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 51 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 42 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 25 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 132 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 307 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 60 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 27 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 81 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 199 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 305 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 61 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 4 | 0.030 |
Why?
| | Health | 1 | 2014 | 83 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 239 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 306 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3342 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 20 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 316 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 31 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 528 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 854 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2015 | 304 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 428 | 0.020 |
Why?
| | Reflex, Stretch | 1 | 1993 | 10 | 0.020 |
Why?
| | Denervation | 1 | 1993 | 25 | 0.020 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 13 | 0.020 |
Why?
| | Venous Pressure | 1 | 1992 | 5 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 753 | 0.020 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 53 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2013 | 79 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 533 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 1995 | 293 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1993 | 325 | 0.020 |
Why?
| | Fingers | 1 | 2013 | 106 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 628 | 0.020 |
Why?
| | Skin Temperature | 1 | 1992 | 31 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 158 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2863 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 9 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 72 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 196 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 262 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 3 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 330 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 23 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 433 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 158 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 784 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 78 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 162 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 32 | 0.020 |
Why?
| | Fever | 1 | 1990 | 310 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 134 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 9 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 176 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 359 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 26 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 39 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 5 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1059 | 0.020 |
Why?
| | Child | 3 | 1997 | 22337 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 375 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 202 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1143 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 483 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 636 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 397 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 342 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 40 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 578 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 696 | 0.010 |
Why?
| | Syncope | 1 | 1986 | 58 | 0.010 |
Why?
| | Blood Proteins | 1 | 1988 | 244 | 0.010 |
Why?
| | Feedback | 1 | 2005 | 177 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 13 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 59 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1604 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 423 | 0.010 |
Why?
| | Affect | 1 | 2007 | 313 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3041 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 105 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 168 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 345 | 0.010 |
Why?
| | Methods | 1 | 1983 | 68 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 187 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 172 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 3 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 599 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 22 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 389 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 54 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 140 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 19 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 17 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 42 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 197 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 115 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 501 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 36 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 255 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 55 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 555 | 0.000 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 90 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 99 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 68 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 158 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 314 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 9 | 0.000 |
Why?
| | Risk | 1 | 1987 | 903 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 117 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 61 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 504 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 404 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1100 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|